2023 Integrated Annual Report
- 11 June 2024 - 1 mins read
In 2023, we reinforced our ambition to be a leading, global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
08 April 2025
0 mins read
2024 Universal Registration Document
17 April 2024
1 mins read
2023 Universal Registration Document
02 June 2023
0 mins read
Information relating to compensation elements of Mr. David Loew, CEO – 31 May 2023
01 June 2023
0 mins read
Compensation policy for corporate officers Combined shareholders’ meeting of 31 May 2023
31 May 2023
1 mins read
2022 Integrated Annual Report
24 April 2023
1 mins read
Generation Ipsen – for positive change
24 April 2023
1 mins read
Ipsen in Brief
06 April 2023
1 mins read
2022 Universal Registration Document
09 February 2023
0 mins read
Information relating to the compensation elements of Mr. David LOEW, Chief Executive Officer
31 May 2022
0 mins read